Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sotorasib in KRAS G12C Mutated NSCLC
NCT05400577Phase 2Withdrawn
- Sponsor
- Fox Chase Cancer Center
- Start
- Jul 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sotorasib in non-small cell lung cancer (NSCLC), sponsored by Fox Chase Cancer Center. Planned start Jul 2022; status: withdrawn.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05400577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400577.